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Introduction
The frequent use of the weak opioid tramadol as a treatment choice for chronic noncancer pain (CNCP), the consequences, and the appropriateness of this treatment have been publicly and scientifically debated and investigated for several years [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] , which emphasises that tramadol treatment for CNCP remains a major global health issue. Interestingly, the extent of tramadol use has evolved differently in the Nordic countries [7] , exemplified by an approximately 70% increase in the number of tramadol users in Denmark during the first decade of the 21st century, which was not seen to the same degree in the other Nordic countries [2, 7, 9] . To date, knowledge of the characteristics of opioid users in Denmark is derived mainly from four self-reported cross-sectional surveys: The Danish National Health and Morbidity Surveys from 2000, 2005, 2010 , and 2013 of approximately 5,500-15,200 inhabitants each. These surveys are all conducted in the same municipality area, so they are more informative regarding longitudinal changes than necessarily representative of the whole country. The response rates have been between 51% and 63%, representing 10,927 individuals in total reporting CNCP (including potential duplicates) showing an increase of both CNCP and prescribed weak opioid use [2, 9] . Knowledge of socioeconomics, demographics, co-medications, and comorbid conditions for CNCP and non-cancer tramadol users is sparse.
Given the public debate regarding tramadol use for the treatment of CNCP, the awareness of the risk of addiction and opioid-induced death when treating with weak opioids [6, 9, [11] [12] [13] [14] , and because of the limited knowledge of the characteristics of users without cancer [15] ; we conducted a nationwide cohort study based on data from the national registries. We were particularly keen to understand the demographics of continued use of tramadol in CNCP since long-term use may be regarded as potentially hazardous. In this study, we hypothesised that patients with a CNCP diagnosis using tramadol differ in socioeconomics, demographics, co-medications, and comorbid conditions from non-cancer tramadol users. If this hypothesis is confirmed, intervention strategies to prevent repeated tramadol use in the two population groups may need to be different. Consequently, the findings may be able to provide additional support for the new Danish recommendations on opioid treatment for CNCP ( Fig. 1) [16, 17] .
Thus, the objectives were to describe the characteristics of non-cancer tramadol user individuals in Denmark, as well as the characteristics of individuals with CNCP using prescribed tramadol, and assess potential risk factors for repeated tramadol use. We investigated sociodemographic, comorbidity, co-medication, and differences between individuals with one and two + purchased prescriptions of tramadol in Denmark.
Methods

Data source and study population
The study cohort was obtained from the Danish National Registers, which hold information on all Danish residents, approximately 5.8 million individuals [18] . These databases
Strong recommendation
Optimise non-pharmacological and pharmacological non-opioid treatment rather than a trial of opioids Do not exceed the maximum dose of 100 mg morphine equivalents in patients who are to be started on treatment with opioids Do not use opioids in patients with current alcohol and/or substance abuse (cons)
Weak recommendation
Consider a trial of opioids when another non-pharmacological and pharmacological treatment has been tested (cons) When another non-pharmacological and pharmacological treatment has been tested, consider a trial of opioids in patients with current psychiatric illness (when the psychiatric illness is under control) In patients with previous alcohol and/or substance abuse, consider a trial of opioids after non-pharmacological and pharmacological nonopioid treatment has been tested Consider limiting the dose of opioids to 50 mg morphine equivalents in patients who are to begin treatment with opioids Consider switching to another opioid in patients who are undergoing opioid treatment that is continuing to cause debilitating pain and/or unacceptable adverse reactions Consider tapering the opioid treatment in patients rather than continuing with an unchanged dose. This consideration, in particular, applies to patients undergoing treatment with 100 mg morphine equivalents or more Consider interdisciplinary input in patients undergoing opioid treatment who wish to taper the treatment but are finding this a considerable challenge A strong recommendation PRO is used when reliable evidence on the overall benefits of the intervention are clearly greater than the disadvantages, and CONS when the overall disadvantages are greater than the benefits, or the intervention are useless. A weak recommendation PRO intervention is given when it is assessed that the benefits of the intervention are marginally greater than the disadvantages, or the available evidence cannot rule out a significant advantage of existing practice, while the adverse effects are few or absent, and CONS when the disadvantages are considered to be greater than the benefits, based on low confidence in the estimated effects, or when the balance between the strong evidence of both beneficial and harmful effects is difficult to determine. Good practice is used when there is no relevant evidence, and thus based exclusively on the professional consensus of the members Working. Further details: https://www.sst.dk/da/udgivelser/2018/~/media/1DC940E1B0C94614B5C15782D6869975.ashx are unique data sources linked by individual social security numbers, giving the opportunity to collate blinded individual information from different databases. We used the Danish National Registry of Patients the Danish National Prescription Database, the Danish Civil Registration System, and the Danish Register of Causes of Death.
The cohort consists of all adults aged 16 years or older who purchased at least one prescription of tramadol in the period 01/01/2004-31/12/2015, with follow-up for a minimum of 1 year after the last purchased tramadol prescription or to the end of 2016. Participants are identified at their first purchased prescription for a tramadol product using the Anatomical Therapeutic Chemical Classification code N02AX02.
Final study population and study design
Our final cancer-free study population consisted of 941,839 men and women, aged 16-110 years, residing in Denmark for ≥5 years before the index year, with a possible follow-up for at least 1 year.
According to the socioeconomic data, we used data from the year before the index year. Information concerning family status was available from 1/1/1999; municipality of residence was available from 1/1/2005 and registered total household income from 1/1/2004. Thus, for patients entering the study in 2004 and 2005, the municipality of housing data for 2005 and the household income data for 2004 were used. Information on the Charlson index, the type of comorbidity, the pain-intensive diagnosis, and the educational level were described based on data in the relevant databases, the numbers of drugs, and the type of co-medication for the index year.
Study conduct
Statistics Denmark approved the study [19] , allocated the permit number 705989 and provided access to the microdata. The data processing and analyses were done using a secure, encrypted Internet connection blinding the identity of the individuals to the investigators. Written informed consent and ethics committee permission was not required since the study was register-based. All authors confirm the accuracy and completeness of the analyses reported.
Tramadol use and CNCP
Treatment initiation is defined as not purchased coverage for an N02AX02 product in the previous 90 days [9, 20] .
Continued use is defined as <90 days between purchased prescriptions for a tramadol product.
We excluded individuals with a cancer diagnosis (ICD10: C00-C11, C13-C15, C17, C20-C22, C24, C25, C30-C32, C34, C37-C41, C45-C49, C52, C55, C64-C66, C70-C72, C74-C83, C85, C88, C90, C92, D00-D02, D38, D42, D43, D46, D47, D90, Z51) ≤5 years before or ≤3 months after first purchased prescription for a tramadol product in the period.
CNCP is defined here as individuals with an ICD10 specific pain-intensive diagnosis mainly chosen from existing research [3] : back/spine pain, headache, neuropathic pain, non-specific/other pain conditions, spondylopathies, disorders of muscles, multimorbid ulcer/skin, adding post-fracture pain and osteoporosis. The first purchased tramadol prescription was interpreted to be because of a CNCP diagnosis, as the criteria for individuals to be allocated to the CNCP group was a CNCP diagnosis ≤1 year before or ≤5 years after the index.
Statistical analyses
We analysed the population of tramadol users concerning the variables presented in Table 1 . We used multiple logistic regression analyses; all covariates were mutually adjusted for significant or borderline significant covariates selected using a critical p < 0.20. The analyses addressed the associations with age, sex, co-medication, comorbidity (ICD-10 codes for hospital contacts, on an inor outpatient basis). Analyses of comparisons between (group A) purchased one prescription of tramadol and (group B) purchased two + prescriptions during the first treatment period (<90 days gap) was conducted. Individuals are included only once.
Demographic data
Age, calculated at the index date, was divided into quartiles. Education level was classified into three categories: primary school ≤10 years, secondary school 11-12 years, and bachelor's degree or higher. Annual household income was divided into lowest sextile ≤150,000 DKR (€ 20,098), lowest tertile ≤200,000 DKR (€ 26,797), middle tertile >200,000 but <400,000 DKR (€ 26,797 -53,594) and highest tertile >400,000 DKR (over € 53,594). All other demographic data follows the registration categories from the registries: marital status, the region of the municipality, the country of origin, and the generation of immigration. 
Results
The cohort consisted of 1,091,602 subjects ( Fig. 2 ). As 101,786 were diagnosed with cancer ≤5 years before or ≤3 months after index, 33,544 died before 1 year of followup, 13,361 had lived in Denmark for <5 years, and 1,071 emigrated before 1 year of follow-up, the final cancer-free cohort for the period 2004-2015 consisted of 941,839 subjects of which 54.4% were women, and the mean age was 53.2 years. Table 1 is a comprehensive description of the baseline characteristics of the study cohort. Briefly, 430,641 (45.7%) had a CNCP diagnosis, and 280,285 (30%) repeated the use of tramadol with two + purchased prescriptions, comprising 56% (N = 155,981) with CNCP diagnosis. The three largest CNCP diagnosis groups were: post-fracture pain, back/spine pain, and non-specific/other pain condition ( Fig. 3) .
A large proportion (76.5%) did not have any record of hospital-treated comorbid conditions, but 52.6% had used ≥four different co-medications in the year before the index. Recent use of anti-rheumatics was widespread, with 81% of the patients being treated the year before index; treatment using beta-blockers is associated with 26.8%, and prednisolone with 22.6% of the cohort. The representation of patients by regions was, as the largest, the Capital Region with 28.1%, and the smallest, the Region of Northern Jutland with 11%; the country of origin was mainly from Denmark with 91.9%, and 99.3% were registered with Danish generations of immigration. The educational level of the cohort amounted to 36.7% with primary school education only, secondary school education 43.6%, a bachelor degree or higher 15.6%, and 4% with unknown educational level. Approximately half of the subjects (52%) were married, and 26% were unmarried.
Characteristics of repeated tramadol use in a cancer-free population
Key characteristics of individuals with repeated tramadol use, defined as purchasing two + prescriptions of tramadol products (<90 days gap) (group B) were statistically compared to individuals purchasing only one prescription (group A); the results are presented in Table 2 .
The logistic regression analyses showed that characteristics associated with an increased risk of repeated tramadol use were unknown educational level, widowed or divorced marital status, male sex, and age groups above the first quartile (41 + years). The CNCP diagnosis included back/spine pain, spondylopathies, multimorbid ulcer/skin, and for men, osteoporosis. First-generation immigrants were also more at risk. The number of any co-medications was a factor for increased risk of repeated use, as was the type of co-medication including ACE inhibitors in total, anti-diabetics, anti-rheumatics, joint and muscular pain, anti-epileptics, Parkinson's medications, other antidepressants, SSRI, and analgesics. Comorbidities play a role overall, in particular, diabetes, and in the total analysis, pulmonary disease, and dementia are also seen prominently.
Also, it was found that characteristics associated with a decreased risk of repeated tramadol use were an education level higher than primary school, a household income above the lowest tertile, or an unknown level of household income. The following CNCP diagnoses: headache, neuropathic pain, non-specific/other pain conditions, and disorders of muscles; most countries of origin except North America, Oceania, and unknown country of origin -but not according to men, and the second generation of immigration in total. Several types of co-medications were associated including anti-hypertension and beta blockers in total and in men, ischemic heart disease, antiarrhythmics, AT2 antagonists, and in women, lipid-lowering, prednisolone, and immunosuppressants total and in men. The comorbidities associated with a decreased risk of repeated tramadol use were both arthritic diseases and heart failure, the latter particularly for women.
Description of CNCP individuals repeated tramadol use
The logistic regression analyses of individuals with repeated tramadol use (group B) were compared to (group A); the results are presented in Table 3 . Characteristics associated with an increased risk of repeated tramadol use were found to be unknown educational level -but not for men; widowed or divorced marital status, the latter, not for women; male sex; and age groups above the first quartile (41 + years). The following CNCP diagnoses: back/spine pain, spondylopathies, osteoporosis, and multimorbid ulcer/skin. Living in the regions of Northern Jutland and Central Jutland were associated with increased risk in both regions, as were being firstgeneration immigrants. The number of any co-medications was a factor for increased risk, as was the type of co-medication as follows: anti-diabetics, anti-rheumatics, joint and muscular pain (not in men), anti-epileptics, Parkinson's medications, other antidepressants, SSRI, and analgesics. The Charlson index co-morbidities overall had an impact: the following type of co-morbidities were noted: pulmonary disease (not in men), and dementia.
A decreased risk of repeated tramadol use was found to be characterised by an education level higher than primary school, a household income above the lowest tertile or an unknown level of household income. The following CNCP diagnoses: post-fracture pain for men, headache, neuropathic pain, non-specific/other pain conditions, and disorders of muscles. Most countries of origin characterised a decreased risk, but this fact was not the case for men from South and Central America, North America and Oceania. Several types of co-medications were included: anti-hypertension total, anticoagulation AC only in the analysis of men, ischemic heart disease, antiarrhythmics, AT2 antagonists, lipidlowering, prednisolone, and immunosuppressants only in men. The comorbidity arthritic diseases characterised a decreased risk of repeated tramadol use for the group of CNCP individuals.
The risk factors of CNCP patients and non-cancer tramadol users in total are illustrated in Table 4 , pointing out the differences between the groups.
Discussion
This study demonstrates the widespread use of tramadol. The nationwide cohort study was conducted in a country with excellent health registers, as well as a country facing challenges of a growing population living with CNCP and an increase of prescribed weak opioid use [2, 9] . The findings are based on the two defined non-overlapping outcome groups (Fig. 2) , describing risk factors associated with repeated tramadol use within a larger-scale national cancer-free cohort of men and women aged 16 + years. Some comorbid conditions, co-medications, as well as demographic and socioeconomic factors, were found to increase or decrease the risk of repeated tramadol use (Tables 2 and 3) . Also, we identified some differences between the group of non-cancer tramadol users and the group of CNCP tramadol users (Table 4 ); these findings are consistent with the study hypothesis that patients who have a CNCP diagnosis differ from the group of other non-cancer tramadol users. The main findings emphasise the differences (Table 4 ) and may, therefore, have implications for considerations and interventions when treating CNCP. Thus, confirming the emphasised risks of the problematic use of tramadol as addressed within the recent clinical guideline [16] and the National Recommendations [21] , those recommendations correspond to the systematic review and meta-analysis investigating the long-term (26-108 weeks) efficacy and the harms of opioids in CNCP. The main weakness of this review was its overwhelming dropout rate, despite which some effects of pain reduction were demonstrated, but only two studies tested tramadol. The authors conclude that long-term opioid therapy could be considered in carefully selected and monitored cases [22] . Another systematic review and meta-analysis comprised of short-term RCT studies (4-12 weeks) compared morphine or tramadol to nonopioid therapy found nonopioid analgesics are superior in terms of improvement of physical function and tolerability. The study does not support therapeutic need for opioids for patients with a CNCP diagnosis [23] . The recommendations for the careful selection and the minor support of opioid therapy for CNCP [16, [21] [22] [23] may underpin a noteworthy problem in CNCP treatment in Denmark, demonstrated in the current study, because almost 60% of the third who continued to use tramadol had CNCP, which can be interpreted as a potentially inappropriate and risky choice of treatment for CNCP [9, 16, 17, 24, 25] .
A general need for improvement in the field may be emphasised based on the literature demonstrating a comprehensive number of long-term tramadol users [2, 9, 16] . Also, it is known that tramadol therapy for CNCP, in many cases leads subsequently to high potent opioid use in an inappropriate treatment path [3, 9] . Moreover, several studies have shown that tramadol-adverse events are essential concerns in the first place [4, 24, 26] .
Although Denmark is a small country, there are some inequalities in income, educational level, and access to health care across the country. We demonstrated that CNCP patients living in the regions of Northern Jutland and Central Jutland generally were at increased risk of repeated tramadol use. The region of Northern Jutland had in 2007 (when the registration of opioid use on a regional level began) the highest level of opioid use in the country (DDD/1,000 inhabitants per day), with a decreased but continued high level over the years. (Table 3) .
Non The region of Central Jutland has had stable opioid use over the years, with levels lower than Northern Jutland but significantly above the Capital Region, which has the lowest level [27] . The population age and educational level may have some impact on the differences between the regions [9] . The comorbidities diabetes, pulmonary disease, and dementia were found to be associated with an increased risk of continued use in analyses presented in Table 2 . In the analyses of individuals with CNCP (Table 3) , diabetes was no longer statistically significant, but in all analyses, the use of anti-diabetics was associated with an increased risk of repeated tramadol use. This factor is considered important and still points to diabetes as a risk factor. Additionally, Fournier and colleagues have demonstrated that tramadol may cause hypoglycemia and risk of hospitalisation [25] . Thus, it may be emphasised that diabetes seems to be a risk factor for repeated tramadol use among CNCP patients, and tramadol use may also be a substantial risk factor for developing diabetes, leading to the need for increased attention towards individuals with diabetes or who are predisposed for developing diabetes.
Currently, the overall educational level above the primary school level was associated with a decreased risk of repeated tramadol use. Educational level is a wellknown factor in health inequality and is associated with CNCP [2, 9] . In a survey study of opioid addiction which analysed 13,281 individuals [13] , long-term opioid users (N = 188) had a larger proportion of the primary school level education (48.1%) compared to short-term users (N = 460, 39.6%). Also, a smaller proportion of individuals without CNCP had the primary school educational level (N = 9,976, 24.9%); thus, the current study findings which emphasise the primary school educational level as a valuable factor to consider in the use of tramadol for the treatment of CNCP.
Being divorced did not seem to affect the level of repeated tramadol use in women. Other studies have found that women seem to cope better with being divorced, single life, chronic illness, and chronic pain compared to men [28] , which is also supported by the finding that single CNCP women had a decreased risk (Table 3 ). This factor was not statistically significant for women presented in Table 2 , suggesting that CNCP women in the current study may possess some resilience.
Limitations
Some deficiencies are suitable to mention regarding register-based studies. Although we have information on the purchased drugs on an individual level, we do not know to what extent the drugs are used; this fact may lead to the potential bias that overestimates drug use. Then again, the potential risk of underestimation is also present, because we do not have information on medication delivered from hospitals/institutions or bought from abroad or the Internet (illicit use). Moreover, information on comorbidities is restricted to in-and outpatient hospital treatment, not including diagnoses from general practitioners; this lack of information is, however, somewhat captured trough information on all filled prescriptions. Non-cancer tramadol user CNCP -Unknown, Country of origin -Pakistan, Country of origin* -The second generation of immigrants* -Anti-hypertension* -Anti-hypertension* -Anti-coagulation AC -Ischemic heart disease* -Ischemic heart disease* -Antiarrhythmics* -Antiarrhythmics* -AT2 antagonists* -AT2 antagonists* -Beta-blockers* -Lipid-lowering* -Lipid-lowering* -Prednisolone* -Prednisolone* -Immunosuppressants -Immunosuppressants* -Arthritic diseases, comorbidity* -Arthritic diseases, comorbidity* -Heart failure, comorbidity* The variable is statistically significant in the analysis of the general population*, men , women . The comprehensive national study population of all men and women aged 16 + using tramadol in the period 01/12/2004-31/12/2016 may be considered as a substantial strength, as well because of the capability to include population-based health and socioeconomic information. The results are considered applicable to other Western countries, in particular, the Nordic countries.
Conclusion
The study showed widespread use of tramadol, which indicates a general need for increased attention generally, and especially for CNCP, incorporating a focus on comorbidities such as diabetes, pulmonary disease, and dementia, as well as osteoporosis. The study also identifies some inequality among CNCP tramadol users in Denmark.
Implications
When striving to reduce the overuse of opioids, a focus on the extensive use of tramadol may be essential. The current study indicates excessive and not-appropriatelyprescribed use of tramadol among Danish CNCP patients. In addition to being inappropriate, such use may also have impacts on the growing problem of an illicit Internet market for this drug. Thus, the situation must be taken seriously. The current study confirms the recent clinical guideline and the National Recommendations in Denmark, which emphasises the risks of problematic use of tramadol. The research may also be relevant in other comparable countries. Caution must especially be taken regarding CNCP patients with comorbidities like diabetes, lung disease, dementia, and osteoporosis.
